Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
aripiprazole
Otsuka Pharmaceutical Netherlands B.V.
N05AX12
aripiprazole
Psycholeptics
Schizophrenia; Bipolar Disorder
Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Abilify is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.
Revision: 49
Authorised
2004-06-04
107 B. PACKAGE LEAFLET 108 PACKAGE LEAFLET: INFORMATION FOR THE USER ABILIFY 5 MG TABLETS ABILIFY 10 MG TABLETS ABILIFY 15 MG TABLETS ABILIFY 30 MG TABLETS aripiprazole READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What ABILIFY is and what it is used for 2. What you need to know before you take ABILIFY 3. How to take ABILIFY 4. Possible side effects 5 How to store ABILIFY 6. Contents of the pack and other information 1. WHAT ABILIFY IS AND WHAT IT IS USED FOR ABILIFY contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics. It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterised by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness. People with this condition may also feel depressed, guilty, anxious or tense. ABILIFY is used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability. In adults it also prevents this condition from returning in patients who have responded to the treatment with ABILIFY. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ABILIFY DO NOT TAKE ABILIFY • if you are allergic to aripiprazole or any of the other ingredients of this medicine (listed in section 6). WARNING Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT ABILIFY 5 mg tablets ABILIFY 10 mg tablets ABILIFY 15 mg tablets ABILIFY 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ABILIFY 5 mg tablets Each tablet contains 5 mg of aripiprazole. Excipient with known effect 63.65 mg lactose (as monohydrate) per tablet _ _ ABILIFY 10 mg tablets Each tablet contains 10 mg of aripiprazole. Excipient with known effect 59.07 mg lactose (as monohydrate) per tablet ABILIFY 15 mg tablets Each tablet contains 15 mg of aripiprazole. Excipient with known effect 54.15 mg lactose (as monohydrate) per tablet ABILIFY 30 mg tablets Each tablet contains 30 mg of aripiprazole. Excip ient with known effect 177.22 mg lactose (as monohydrate) per tablet For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet ABILIFY 5 mg tablets Rectangular and blue, engraved with "A-007" and "5" on one side. ABILIFY 10 mg tablets Rectangular and pink, engraved with "A-008" and "10" on one side. ABILIFY 15 mg tablets Round and yellow, engraved with "A-009" and "15" on one side. ABILIFY 30 mg tablets Round and pink, engraved with "A-011" and "30" on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ABILIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. 3 ABILIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1). ABILIFY is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults _ _ _ _Schizophrenia:_ the recommended starting dose for ABILIFY is 10 mg/day or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to Przeczytaj cały dokument